Moreover, the addition of simvastatin to mFOLFOX6 + cetuximab was shown to increase the efficacy of FOLFOX6 + cetuximab, reduce the incidence of side effects, including peripheral neuropathy, and prolong OS of KRAS-mutated colorectal cancer patients [46]. This evidence concerns the gene KRAS and colorectal cancer.